Shots:

• In H1’21- Celltrion plans to initiate P-III trial for CT-P41 and is expected to commercialize in Feb 2025 when Amgen’s patents for Prolia expire in the US
• Celltrion is also planning for the onset of P-III for CT-P16 in H1’21 targeted for metastatic colorectal cancer- metastatic breast cancer- and non–small cell lung cancer. Additionally- one of its biosimilar CT-P39 is currently evaluated in P-I trial with expected P-III trial initiation in 2022
• CT-P41 is a mAb a biosimilar to Amgen Prolia (denosumab) targets receptor activator of nuclear factor-kappa-Β ligand (RANKL) proteins in patients with osteoporosis

Ref: Celltrion | Image: Celltrion